Plozalizumab
Monoclonal antibody
- none
- 1610761-46-0
- none
- 4XG66BMN0D
- D10972
Plozalizumab (INN; hu1D9) is a humanized monoclonal antibody designed for the treatment of diabetic nephropathy and arteriovenous graft patency.[1][2]
This drug was developed by Takeda Pharmaceuticals International Co.
References
- v
- t
- e
Monoclonal antibodies for the immune system
Human | |
---|---|
Humanized | |
Veterinary |
Mouse |
|
---|
- #WHO-EM
- ‡Withdrawn from market
- Clinical trials:
- †Phase III
- §Never to phase III
This monoclonal antibody–related article is a stub. You can help Wikipedia by expanding it. |
- v
- t
- e